These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 28247193)

  • 1. Modeling a Composite Score in Parkinson's Disease Using Item Response Theory.
    Gottipati G; Karlsson MO; Plan EL
    AAPS J; 2017 May; 19(3):837-845. PubMed ID: 28247193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Item Response Model Adaptation for Analyzing Data from Different Versions of Parkinson's Disease Rating Scales.
    Gottipati G; Berges AC; Yang S; Chen C; Karlsson MO; Plan EL
    Pharm Res; 2019 Jul; 36(9):135. PubMed ID: 31317279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort.
    Regnault A; Boroojerdi B; Meunier J; Bani M; Morel T; Cano S
    J Neurol; 2019 Aug; 266(8):1927-1936. PubMed ID: 31073716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gender-, age-, and race/ethnicity-based differential item functioning analysis of the movement disorder society-sponsored revision of the Unified Parkinson's disease rating scale.
    Goetz CG; Liu Y; Stebbins GT; Wang L; Tilley BC; Teresi JA; Merkitch D; Luo S
    Mov Disord; 2016 Dec; 31(12):1865-1873. PubMed ID: 27943473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results.
    Goetz CG; Tilley BC; Shaftman SR; Stebbins GT; Fahn S; Martinez-Martin P; Poewe W; Sampaio C; Stern MB; Dodel R; Dubois B; Holloway R; Jankovic J; Kulisevsky J; Lang AE; Lees A; Leurgans S; LeWitt PA; Nyenhuis D; Olanow CW; Rascol O; Schrag A; Teresi JA; van Hilten JJ; LaPelle N;
    Mov Disord; 2008 Nov; 23(15):2129-70. PubMed ID: 19025984
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the Hebrew version of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale.
    Zitser J; Peretz C; Ber David A; Shabtai H; Ezra A; Kestenbaum M; Brozgol M; Rosenberg A; Herman T; Balash Y; Gadoth A; Thaler A; Stebbins GT; Goetz CG; Tilley BC; Luo ST; Liu Y; Giladi N; Gurevich T
    Parkinsonism Relat Disord; 2017 Dec; 45():7-12. PubMed ID: 28965872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Parkinson's Disease Composite Scale: results of the first validation study.
    Stocchi F; Radicati FG; Chaudhuri KR; Johansson A; Padmakumar C; Falup-Pecurariu C; Martinez-Martin P
    Eur J Neurol; 2018 Mar; 25(3):503-511. PubMed ID: 29193455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measuring Parkinson's disease over time: The real-world within-subject reliability of the MDS-UPDRS.
    Evers LJW; Krijthe JH; Meinders MJ; Bloem BR; Heskes TM
    Mov Disord; 2019 Oct; 34(10):1480-1487. PubMed ID: 31291488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Item Response Theory as an Efficient Tool to Describe a Heterogeneous Clinical Rating Scale in De Novo Idiopathic Parkinson's Disease Patients.
    Buatois S; Retout S; Frey N; Ueckert S
    Pharm Res; 2017 Oct; 34(10):2109-2118. PubMed ID: 28695401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanded and independent validation of the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS).
    Martinez-Martin P; Rodriguez-Blazquez C; Alvarez-Sanchez M; Arakaki T; Bergareche-Yarza A; Chade A; Garretto N; Gershanik O; Kurtis MM; Martinez-Castrillo JC; Mendoza-Rodriguez A; Moore HP; Rodriguez-Violante M; Singer C; Tilley BC; Huang J; Stebbins GT; Goetz CG
    J Neurol; 2013 Jan; 260(1):228-36. PubMed ID: 22865238
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort.
    Simuni T; Caspell-Garcia C; Coffey CS; Weintraub D; Mollenhauer B; Lasch S; Tanner CM; Jennings D; Kieburtz K; Chahine LM; Marek K
    J Neurol Neurosurg Psychiatry; 2018 Jan; 89(1):78-88. PubMed ID: 28986467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan.
    Goetz CG; Fahn S; Martinez-Martin P; Poewe W; Sampaio C; Stebbins GT; Stern MB; Tilley BC; Dodel R; Dubois B; Holloway R; Jankovic J; Kulisevsky J; Lang AE; Lees A; Leurgans S; LeWitt PA; Nyenhuis D; Olanow CW; Rascol O; Schrag A; Teresi JA; Van Hilten JJ; LaPelle N
    Mov Disord; 2007 Jan; 22(1):41-7. PubMed ID: 17115387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments.
    Lang AE; Eberly S; Goetz CG; Stebbins G; Oakes D; Marek K; Ravina B; Tanner CM; Shoulson I;
    Mov Disord; 2013 Dec; 28(14):1980-6. PubMed ID: 24123383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting Progression in Parkinson's Disease Using Baseline and 1-Year Change Measures.
    Chahine LM; Siderowf A; Barnes J; Seedorff N; Caspell-Garcia C; Simuni T; Coffey CS; Galasko D; Mollenhauer B; Arnedo V; Daegele N; Frasier M; Tanner C; Kieburtz K; Marek K;
    J Parkinsons Dis; 2019; 9(4):665-679. PubMed ID: 31450510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between the Movement Disorders Society Unified Parkinson's Disease rating scale (MDS-UPDRS) and the Unified Parkinson's Disease rating scale (UPDRS) during L-dopa acute challenge.
    Merello M; Gerschcovich ER; Ballesteros D; Cerquetti D
    Parkinsonism Relat Disord; 2011 Nov; 17(9):705-7. PubMed ID: 21784692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression of MDS-UPDRS Scores Over Five Years in De Novo Parkinson Disease from the Parkinson's Progression Markers Initiative Cohort.
    Holden SK; Finseth T; Sillau SH; Berman BD
    Mov Disord Clin Pract; 2018; 5(1):47-53. PubMed ID: 29662921
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using cognitive pretesting in scale development for Parkinson's disease: the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) example.
    Tilley BC; LaPelle NR; Goetz CG; Stebbins GT;
    J Parkinsons Dis; 2014; 4(3):395-404. PubMed ID: 24613868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Large-scale identification of clinical and genetic predictors of motor progression in patients with newly diagnosed Parkinson's disease: a longitudinal cohort study and validation.
    Latourelle JC; Beste MT; Hadzi TC; Miller RE; Oppenheim JN; Valko MP; Wuest DM; Church BW; Khalil IG; Hayete B; Venuto CS
    Lancet Neurol; 2017 Nov; 16(11):908-916. PubMed ID: 28958801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between the non-motor items of the MDS-UPDRS and Quality of Life in patients with Parkinson's disease.
    Skorvanek M; Rosenberger J; Minar M; Grofik M; Han V; Groothoff JW; Valkovic P; Gdovinova Z; van Dijk JP
    J Neurol Sci; 2015; 353(1-2):87-91. PubMed ID: 25918077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using Movement Disorder Society Unified Parkinson's Disease Rating Scale Parts 2 and 3 Simultaneously: Combining the Patient Voice with Clinician Ratings.
    Guo Y; Goetz CG; Stebbins GT; Mestre TA; Luo S
    Mov Disord; 2023 Mar; 38(3):453-463. PubMed ID: 36621935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.